研究者業績

志賀 守

shiga mamoru

基本情報

所属
藤田医科大学 医学部 医学科 呼吸器内科学Ⅱ 講師
学位
博士(医学)

J-GLOBAL ID
200901097340979330
researchmap会員ID
5000024816

MISC

 18
  • Tadao Nagasaki, Hisako Matsumoto, Yoshihiro Kanemitsu, Kenji Izuhara, Yuji Tohda, Hideo Kita, Takahiko Horiguchi, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura, Noriyuki Ohkura, Katsuyuki Tomita, Akihito Yokoyama, Hiroshi Ohnishi, Yasutaka Nakano, Tetsuya Oguma, Soichiro Hozawa, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Toshiyuki Iwata, Yumi Izuhara, Junya Ono, Shoichiro Ohta, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 133(5) 1474-U406 2014年5月  
  • Y. Izuhara, H. Matsumoto, Y. Kanemitsu, K. Izuhara, Y. Tohda, T. Horiguchi, H. Kita, K. Kuwabara, K. Tomii, K. Otsuka, M. Fujimura, N. Ohkura, K. Tomita, A. Yokoyama, H. Ohnishi, Y. Nakano, T. Oguma, S. Hozawa, T. Nagasaki, I. Ito, T. Oguma, H. Inoue, T. Tajiri, T. Iwata, J. Ono, S. Ohta, M. Tamari, T. Hirota, T. Yokoyama, A. Niimi, M. Mishima
    ALLERGY 69(5) 668-673 2014年5月  
    Background In steroid-naive patients with asthma, several gene variants are associated with a short-term response to inhaled corticosteroid (ICS) treatment; this has mostly been observed in Caucasians. However, not many studies have been conducted for other ethnicities. Here, we aimed to determine the relationship between the annual decline in forced expiratory flow volume in one second (FEV1) and the variant of the glucocorticoid-induced transcript 1 gene (GLCCI1) in Japanese patients with asthma receiving long-term ICS treatment, taking into account the effect of high serum periostin levels, a known association factor of pulmonary function decline and a marker of refractory eosinophilic/Th2 inflammation. Methods In this study, 224 patients with asthma receiving ICS treatment for at least 4years were enrolled. The effects of single-nucleotide polymorphisms (SNPs) in GLCCI1, stress-induced phosphoprotein 1 (STIP1), and T gene on the decline in FEV1 of 30ml/year or greater were determined. Results Besides the known contributing factors, that is, the most intensive treatment step, ex-smoking, and high serum periostin levels (>= 95ng/ml), the GG genotype of GLCCI1 rs37973, and not other SNPs, was independently associated with a decline in FEV1 of 30ml/year or greater. When patients were stratified according to their serum periostin levels, the GG genotype of rs37973 was significantly associated with blood eosinophilia (>= 250/mu l) in the high serum periostin group. Conclusions A GLCCI1 variant is a risk factor of pulmonary function decline in Japanese patients with asthma receiving long-term ICS treatment. Thus, GLCCI1 may be associated with response to ICS across ethnicities.
  • Yoshihiro Kanemitsu, Hisako Matsumoto, Kenji Izuhara, Yuji Tohda, Hideo Kita, Takahiko Horiguchi, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura, Noriyuki Ohkura, Katsuyuki Tomita, Akihito Yokoyama, Hiroshi Ohnishi, Yasutaka Nakano, Tetsuya Oguma, Soichiro Hozawa, Tadao Nagasaki, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Toshiyuki Iwata, Yumi Izuhara, Junya Ono, Shoichiro Ohta, Mayumi Tamari, Tomomitsu Hirota, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 132(2) 305-+ 2013年8月  
    Background: Periostin, an extracellular matrix protein, contributes to subepithelial thickening in asthmatic airways, and its serum levels reflect airway eosinophilic inflammation. However, the relationship between periostin and the development of airflow limitation, a functional consequence of airway remodeling, remains unknown. Objective: We aimed to determine the relationship between serum periostin levels and pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. Methods: Two hundred twenty-four asthmatic patients (average age, 62.3 years) treated with ICS for at least 4 years were enrolled. Annual changes in FEV1, from at least 1 year after the initiation of ICS treatment to the time of enrollment or later (average, 16.2 measurements over 8 years per individual), were assessed. At enrollment, clinical indices, biomarkers that included serum periostin, and periostin gene polymorphisms were examined. Associations between clinical indices or biomarkers and a decline in FEV1 of 30 mL or greater per year were analyzed. Results: High serum periostin levels (>= 95 ng/mL) at enrollment, the highest treatment step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL or greater per year. Multivariate analysis showed that high serum periostin, the highest treatment step, and ex-smoking were independent risk factors for the decline. Polymorphisms of periostin gene were related to higher serum periostin levels (rs3829365) and a decline in FEV1 of 30 mL or greater per year (rs9603226). Conclusions: Serum periostin appears to be a useful biomarker for the development of airflow limitation in asthmatic patients on ICS.
  • Yoshihiro Kanemitsu, Hisako Matsumoto, Kenji Izuhara, Yuji Tohda, Hideo Kita, Takahiko Horiguchi, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura, Noriyuki Ohkura, Katsuyuki Tomita, Akihito Yokoyama, Hiroshi Ohnishi, Yasutaka Nakano, Tetsuya Oguma, Soichiro Hozawa, Tadao Nagasaki, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Tomoko Tajiri, Toshiyuki Iwata, Yumi Izuhara, Junya Ono, Shoichiro Ohta, Mayumi Tamari, Tomomitsu Hirota, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 132(2) 305-+ 2013年8月  
    Background: Periostin, an extracellular matrix protein, contributes to subepithelial thickening in asthmatic airways, and its serum levels reflect airway eosinophilic inflammation. However, the relationship between periostin and the development of airflow limitation, a functional consequence of airway remodeling, remains unknown. Objective: We aimed to determine the relationship between serum periostin levels and pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. Methods: Two hundred twenty-four asthmatic patients (average age, 62.3 years) treated with ICS for at least 4 years were enrolled. Annual changes in FEV1, from at least 1 year after the initiation of ICS treatment to the time of enrollment or later (average, 16.2 measurements over 8 years per individual), were assessed. At enrollment, clinical indices, biomarkers that included serum periostin, and periostin gene polymorphisms were examined. Associations between clinical indices or biomarkers and a decline in FEV1 of 30 mL or greater per year were analyzed. Results: High serum periostin levels (>= 95 ng/mL) at enrollment, the highest treatment step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL or greater per year. Multivariate analysis showed that high serum periostin, the highest treatment step, and ex-smoking were independent risk factors for the decline. Polymorphisms of periostin gene were related to higher serum periostin levels (rs3829365) and a decline in FEV1 of 30 mL or greater per year (rs9603226). Conclusions: Serum periostin appears to be a useful biomarker for the development of airflow limitation in asthmatic patients on ICS.
  • 伴直昭, 廣瀬正裕, 桑原和伸, 畑秀治, 那須利憲, 大平大介, 志賀守, 近藤りえ子, 堀口高彦
    日本職業アレルギー学会雑誌 20(2) 2013年  
  • 大平大介, 志賀守, 桑原和伸, 伴直昭, 畑秀治, 那須利憲, 廣瀬正裕, 近藤りえ子, 堀口高彦
    日本職業アレルギー学会雑誌 20(2) 2013年  
  • 志賀 守, 伴 直昭, 桑原 和伸, 畑 秀治, 大平 大介, 那須 利憲, 廣瀬 正裕, 近藤 りえ子, 堀口 高彦
    日本胸部臨床 71(12) 1254-1260 2012年12月  
    近年COPDは全身性炎症性疾患と認識されるようになり、さらにスタチンの使用がCOPDの生命予後改善に寄与するとの報告がなされるようになった。本研究では、血清脂質異常症を合併したCOPD患者に対するピタバスタチンの有用性を検討した。当施設通院中の%FEV1が50%以上の血清脂質異常症合併COPD患者26例で、文書同意が得られた患者を対象とした。ピタバスタチン投与前と投与3ヵ月後に炎症性マーカーを測定し比較検討した。結果、ピタバスタチン投与3ヵ月後で高感度CRPは有意に低下した(2,778.8±4,713.9ng/ml、1,035.9±1,598.7ng/ml、p=0.0083)。スタチンはCOPDの全身性炎症に有用である可能性が示唆された。(著者抄録)
  • 近藤りえ子, 廣瀬正裕, 宮本明子, 桑原和伸, 伴直昭, 畑秀治, 那須利憲, 大平大介, 志賀守, 堀口高彦, 宇野浩生, 仙田典保, 長谷川森一, 小林花神
    Progress in Medicine第11号 32(410) 189-193 2012年  
  • 志賀守, 堀口高彦
    THE LUNG 20(2) 2012年  
  • 廣瀬正裕, 桑原和伸, 伴直昭, 畑秀治, 那須利憲, 大平大介, 志賀守, 近藤りえ子, 堀口高彦
    日本胸部臨床 71(5) 2012年  
  • 堀口高彦, 近藤りえ子, 伴 直昭, 桑原和伸, 畑 秀治, 那須利憲, 大平大介, 廣瀬正裕, 志賀 守, 小林花神, 長谷川森一
    PRODRESS IN MEDICINE 31(10) 161-163 2011年  
  • 桑原和伸, 志賀守, 伴直昭, 畑秀治, 大平大介, 那須利憲, 小林花神, 廣瀬正裕, 近藤りえ子, 堀口高彦
    藤田学園医学会誌(短報) 35(1) 41-44 2011年  
  • 伴直昭, 近藤りえ子, 桑原和伸, 畑秀治, 那須利憲, 大平大介, 廣瀬正裕, 志賀守, 宇野浩生, 仙田典保, 堀口高彦
    藤田学園医学会誌(短報) 35(1) 45-48 2011年  
  • 堀口高彦, 近藤りえ子, 伴直昭, 桑原和伸, 畑秀治, 那須利憲, 大平大介, 小林花神, 廣瀬正裕, 志賀守, 宇野浩生, 仙田典保
    アレルギー免疫6 17(6) 108-115 2010年  
  • 堀口高彦, 近藤りえ子, 伴 直昭, 桑原和伸, 畑 秀治, 那須利憲, 大平大介, 廣瀬正裕, 志賀 守, 小林花神, 長谷川森一
    アレルギー・免疫(2011年9月号) 18(10) 114-120 2010年  
  • 堀口高彦, 滝田好一郎, 桑原和伸, 伴 直昭, 畑 秀治, 大竹洋一郎, 那須利憲, 大平大介, 廣瀬正裕, 志賀 守, 宮崎淳一, 立川壮一, 小林花神, 坂野健吾, 近藤りえ子
    Allergology&Immunology 16(3) 124-130 2009年  
  • 堀口高彦, 桑原和伸, 伴 直昭, 畑 秀治, 大竹洋一郎, 那須利憲, 大平大介, 小林花神, 廣瀬正裕, 志賀 守, 近藤りえ子
    新薬と臨床 58(6号別冊) 2009年  

講演・口頭発表等

 51